Scarica l'app Stockscreener
43.32
1.50%
0.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$42.68
Aprire:
$42.72
Volume 24 ore:
719.02K
Relative Volume:
0.95
Capitalizzazione di mercato:
$2.43B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
40.50
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+2.73%
1M Prestazione:
+30.36%
6M Prestazione:
+31.07%
1 anno Prestazione:
+24.88%
Intervallo 1D:
$42.67
$43.54
Intervallo di 1 settimana:
$41.78
$43.73
Portata 52W:
$29.16
$43.73
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
43.32 | 2.41B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
155.61 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.31 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.80 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
310.66 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. PossibleJuly 2025 PostEarnings & Consistent Income Trade Ideas - newsyoung.net
This Insider Has Just Sold Shares In Supernus Pharmaceuticals - simplywall.st
Insider Sell: Bethany Sensenig Sells 5,369 Shares of Supernus Ph - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD By Investing.com - Investing.com Australia
Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD - Investing.com
Is Supernus Pharmaceuticals, Inc. exposed to political riskTrade Risk Report & AI Optimized Trade Strategies - mustnews.co.kr
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Dividend Review & Fast Entry High Yield Tips - classian.co.kr
Published on: 2025-08-17 09:07:05 - metal.it
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Live market analysis of Supernus Pharmaceuticals Inc.July 2025 Movers & High Yield Equity Trading Tips - Newser
What moving averages say about Supernus Pharmaceuticals Inc.Rate Cut & Daily Risk Controlled Trade Plans - Newser
Is Supernus Pharmaceuticals Inc. stock ready for a breakoutMarket Growth Summary & Risk Managed Trade Strategies - Newser
Will Supernus Pharmaceuticals Inc. stock go up soonMarket Rally & Safe Entry Trade Reports - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyProfit Target & Advanced Swing Trade Entry Alerts - Newser
Technical signs of recovery in Supernus Pharmaceuticals Inc.Quarterly Trade Report & Comprehensive Market Scan Insights - Newser
Is Supernus Pharmaceuticals Inc. forming a bottoming baseMarket Performance Recap & Technical Confirmation Trade Alerts - Newser
Is Supernus Pharmaceuticals Inc. the Top Chart Pick This WeekInflation Watch & AI Powered Market Entry Strategies - sundaytimes.kr
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Movers & Long-Term Safe Investment Plans - newsimpact.co.kr
PNC Financial Services Group Inc. Acquires 726 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know | FinancialContent - FinancialContent
These Three Healthcare Cos. Could Inject New Life Into an Ailing Portfolio - TheStreet Pro
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - Newser
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. Possible [Portfolio Gains Report]Free Daily Stock Momentum Reports - 선데이타임즈
Supernus Pharmaceuticals' Accrual Ratio and Unusual Items Impact Earnings - AInvest
Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are - Yahoo Finance
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade - Yahoo Finance
5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call - ca.finance.yahoo.com
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
Supernus Pharmaceuticals shares rise 1.48% intraday after Lotus Pharmaceuticals reported a 6% revenue increase in the first half of 2025. - AInvest
Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil
How to recover losses in Supernus Pharmaceuticals Inc. stockFree Chart Alert System With Entry Targets - Newser
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionShort-Term Support and Resistance Forecast - Newser
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Australia
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hudson Frederick M. | Director |
Aug 14 '25 |
Sale |
42.26 |
7,457 |
315,133 |
46,307 |
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):